The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers

Antiviral Therapy

Volumn 15, Issue 2, 2010, Pages 227-233

  Randell, Paul A ^a   Jackson, Akil G ^a   Zhong, Lijie ^b   Yale, Kitty ^b   Moyle, Graeme J ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUCOSE; INSULIN; LEPTIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PADGEM PROTEIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLAMP; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG USE; FATIGUE; GLUCOSE TRANSPORT; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HYPERINSULINEMIC EUGLYCEMIC CLAMP; INJURY; INSULIN SENSITIVITY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; VOLUNTEER;

ADENINE; ADIPOKINES; ADULT; ANTI-HIV AGENTS; CHOLESTEROL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; GLUCOSE CLAMP TECHNIQUE; HIV SERONEGATIVITY; HUMANS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; MALE; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950688114     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1518     Document Type: Article

References (35)

1. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-299.
2. Lundgren J, Reiss P, Worm S, et al. Risk of myocardial infarction with exposure to specific ARV from the PI, NNRTI, and NRTI drug classes: the D:A:D study. Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 44LB.
3. De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients the data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care 2008; 31:1224-1229.
4. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48-62. (Pubitemid 40075680)
5. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237:E214-E23. (Pubitemid 9249478)
6. Lee GA, Lo JC, Aweeka F, et al. Single-dose lopinavirritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis 2006; 43:658-660. (Pubitemid 44267131)
7. Lee GA, Rao M, Mulligan K, et al. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. AIDS 2007; 21:2183-2190. (Pubitemid 350287216)
8. Noor MA, Flint OP, Maa J-F, Parker RA. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006; 20:1813-1821.
9. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001; 15:F11-F18. (Pubitemid 32424384)
10. Noor MA, Parker RA, O'Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004; 18:2137-2144. (Pubitemid 39463678)
11. Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002; 16:F1-F8. (Pubitemid 34274457)
12. Blumer RME, vanVonderen MGA, Sutinen J, et al. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting antiretroviral therapy. AIDS 2008; 22:227-236.
13. Fleischman A, Johnsen S, Systrom DM, et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab 2007; 292:E1666-E1673. (Pubitemid 47084702)
14. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275:20251-20254. (Pubitemid 30457596)
15. Lee GA, Seneviratne T, Noor MA, et al. The metabolic effects of lopinavir/ritonavir in HIV negative men. AIDS 2004; 18:641-649. (Pubitemid 38393463)
16. Lee GA, Mafong DD, Noor MA, et al. HIV protease inhibitors increase adiponectin levels in HIV-negative men. J Acquir Immune Defic Syndr 2004; 36:645-647.
17. Birkus G, Hitchcock MJM, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46:716-723. (Pubitemid 34157656)
18. Jackson A, Patel N, Lo G, Gazzard B, Moyle G. Effects of atazanavir or saquinavir QD with ritonavir 100 mg and tenofovir/emtricitabine as initial therapy for HIV-1 infection on peripheral glucose disposal; a randomised open-label study. Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Poster 818.
19. Randell P, Jackson A, Taylor J, Mandalia S, Moyle G. The effects of fosamprenavir or lopinavir with ritonavir, lamivudine and tenofovir, as initial treatment for HIV-1 infection, on insulin sensitivity. 11th European AIDS Conference. 24-27 October 2007, Madrid, Spain. Poster LBP92/1.
20. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients. JAMA 2004; 292:191-201. (Pubitemid 38917996)
21. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients. J Acquir Immune Defic Syndr 2008; 47:74-78.
22. 22. Moyle GJ, Sabin C, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20:2043-2050. (Pubitemid 44611057)
23. Ananworanich J, Nuesch R, Côté HC, et al. Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine - a Staccato trial substudy. J Antimicrob Chemother 2008; 61:1340-1343. (Pubitemid 351753605)
24. Fisher M, Moyle GJ, Shahmanesh M, et al. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir DF/emtricitabine in efavirenztreated HIV-1 infected individuals. J Acquir Immune Defic Syndr 2009; 51:562-568.
25. Tungsiripat M, Kitch D, Glesby M, et al. A pilot study to determine the effect on dyslipidemia of the addition of tenofovir to stable background ART in HIV-infected subjects: results from the A5206 Study Team. Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 714.
26. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7:941-946.
27. Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 277:25863-25866.
28. Welt CK, Chan JL, Bullen J, et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 2004; 351:987-997.
29. Chan JL, Matarese G, Shetty GK, et al. Differential regulation of metabolic, neuroendocrine, and immune function by leptin in humans. Proc Natl Acad Sci USA 2006; 103:8481-8486.
30. Ahima RS, Prabakaran D, Mantzoros C, et al. Role of leptin in the neuroendocrine response to fasting. Nature 1996; 382:250-252.
31. Jan V, Cervera P, Maachi M, et al. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV- 1-infected lipodystrophic patients. Antivir Ther 2004; 9:555-564.
32. Kohler HP, Grant PJ. Plasminogen-activator inhibitor and coronary heart disease. N Engl J Med 2000; 342:1792-1801.
33. Koppel K, Bratt G, Schulman S, Bylund H, Sandström E. Hypofibrinolytic state in HIV-1-infectecl patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 29:441-449.
34. Sipsas NV, Sfikakis PP, Touloumi G, Pantazis N, Choremi H, Kordossis T. Elevated serum levels of soluble immune activation markers are associated with increased risk for death in HAART-naive HIV-1-infected patients. AIDS Patient Care STDS 2003; 17:147-153.
35. Mu H, Chai H, Lin PH, Yao Q, Chen C. Current update on HIV-associated vascular disease and endothelial dysfunction. World J Surg 2007; 31:632-643.